Amicus Therapeutics, Inc. (NASDAQ:FOLD) rose 5.1% during trading on Monday following a better than expected earnings announcement. The stock traded as high as $13.90 and last traded at $13.90, with a volume of 3,148,423 shares trading hands. The stock had previously closed at $13.23.

The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.03. During the same quarter in the prior year, the company posted ($0.40) earnings per share.

Several research analysts have recently weighed in on the stock. BidaskClub cut shares of Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 2nd. Robert W. Baird upped their price target on shares of Amicus Therapeutics from $12.00 to $15.00 and gave the company an “outperform” rating in a report on Wednesday, July 12th. Cowen and Company reiterated a “buy” rating and issued a $16.00 price target (up previously from $10.00) on shares of Amicus Therapeutics in a report on Tuesday, July 11th. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 19th. Finally, ValuEngine upgraded shares of Amicus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $13.42.

In other Amicus Therapeutics news, major shareholder Life Sciences Maste Perceptive bought 1,500,000 shares of Amicus Therapeutics stock in a transaction that occurred on Thursday, July 13th. The stock was acquired at an average price of $12.25 per share, for a total transaction of $18,375,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Hung Do sold 29,914 shares of the stock in a transaction on Friday, May 19th. The stock was sold at an average price of $8.00, for a total transaction of $239,312.00. Following the transaction, the insider now owns 474,438 shares of the company’s stock, valued at approximately $3,795,504. The disclosure for this sale can be found here. 3.40% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Amicus Therapeutics by 4.2% in the first quarter. Vanguard Group Inc. now owns 8,687,760 shares of the biopharmaceutical company’s stock valued at $61,944,000 after buying an additional 353,949 shares during the last quarter. Palo Alto Investors LLC boosted its position in shares of Amicus Therapeutics by 23.0% in the first quarter. Palo Alto Investors LLC now owns 7,882,988 shares of the biopharmaceutical company’s stock valued at $56,206,000 after buying an additional 1,472,958 shares during the last quarter. Janus Capital Management LLC boosted its position in shares of Amicus Therapeutics by 3.6% in the first quarter. Janus Capital Management LLC now owns 7,136,697 shares of the biopharmaceutical company’s stock valued at $50,883,000 after buying an additional 244,906 shares during the last quarter. Morgan Stanley boosted its position in shares of Amicus Therapeutics by 99.4% in the first quarter. Morgan Stanley now owns 6,128,481 shares of the biopharmaceutical company’s stock valued at $43,696,000 after buying an additional 3,055,039 shares during the last quarter. Finally, State Street Corp boosted its position in shares of Amicus Therapeutics by 0.9% in the first quarter. State Street Corp now owns 5,766,929 shares of the biopharmaceutical company’s stock valued at $41,118,000 after buying an additional 50,982 shares during the last quarter.

The company has a 50-day moving average of $11.40 and a 200 day moving average of $8.12. The firm’s market capitalization is $1.99 billion.

TRADEMARK VIOLATION NOTICE: “Amicus Therapeutics, Inc. (FOLD) Stock Price Up 5.1% Following Earnings Beat” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/08/08/amicus-therapeutics-inc-fold-stock-price-up-5-1-following-earnings-beat.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.